Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

@article{Haubrich2009MetabolicOI,
  title={Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.},
  author={Richard Haubrich and Sharon A. Riddler and A Gregory Dirienzo and Lauren Komarow and William G. Powderly and Karin L. Klingman and Kevin W Garren and David L Butcher and James F. Rooney and David W. Haas and John W Mellors and Diane V. Havlir},
  journal={AIDS},
  year={2009},
  volume={23 9},
  pages={1109-18}
}
BACKGROUND The metabolic effects of initial therapy for HIV-1 infection are important determinants of regimen selection. METHODS Open-label study in 753 subjects randomized equally to efavirenz or lopinavir/ritonavir(r) plus two nucleoside reverse-transcriptase inhibitor (NRTI) vs. the NRTI-sparing regimen of lopinavir/r plus efavirenz. Zidovudine, stavudine, or tenofovir with lamivudine was selected prior to randomization. Metabolic outcomes through 96 weeks were lipoatrophy, defined as at… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 109 extracted citations

European mitochondria l DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS

Todd Hulgana, Richard Haubrichb, +5 authors Jeffrey A. Cantera
2010
View 4 Excerpts
Highly Influenced

Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2014
View 4 Excerpts
Highly Influenced

Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients.

Journal of acquired immune deficiency syndromes • 2014
View 4 Excerpts
Highly Influenced

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2011
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 32 references

on Antiretroviral Guidelines for Adults and Adolescents

DHHS Pane
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih. gov; 2003. [Accessed 12 December • 2008
View 3 Excerpts
Highly Influenced

Class-sparing regimens for initial treatment of HIV-1 infection.

The New England journal of medicine • 2008
View 6 Excerpts

Group Metabolic Subcommittee

AIDS Clinical Trial
AACTG Standard Operating Procedures for Whole-Body DEXA Scans Performed for Body Composition Measurements and Regional (Hip and Spine) DEXA Scans Performed for Bone Mineral Density Studies. http://aactg.s3.com/Members/download/final/ asop/dexas.doc. [Accessed December • 2008
View 1 Excerpt

Body composition changes in ARV-naive subjects treated with atazanavir or atazanavir/ritonavir-based once-daily HAART: 96-week CT and DEXA data

G McComsey, R Rightmire, +3 authors D. McGrath
Proceedings of the 11th European AIDS Conference; • 2007

Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2006

Similar Papers

Loading similar papers…